Sotatercept significantly increased the distance that cardiovascular patients could walk over a 24-week period. Patients in the trial also saw improvements in eight of the nine outcome measures for cardiovascular patients set by the World Health Organization.
The trial also found sotatercept reduced the risk of clinical worsening or death by 84 percent compared to a placebo, according to a March 6 press release.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
